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Autophagy, a highly regulated cell “self-eating” pathway, is controlled by the action of over
34 autophagy-related proteins (collectively termed Atgs). Although they are fundamentally
different processes, autophagy and apoptosis (type I programmed cell death), under certain
circumstances, can be regulated by common signaling mediators. Current cancer thera-
pies including chemotherapy and ionizing radiation are known to induce autophagy within
tumor cells. However, autophagy plays a dual role of either pro-cell survival or pro-cell death
in response to these cancer treatments, depending on the cellular context and the nature
of the treatment. We review the current basic and translational cancer research literature
on how autophagy impacts tumor cell survival (“to live”) and death (“not to live”) following
treatment as well as the role of chemical mediators of autophagy.
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INTRODUCTION
An apoptotic response in tumors cells has been shown to play a
major role in determining the cytotoxicity in response to DNA
damaging agents such as ionizing radiation and several different
classes of chemotherapeutic drugs (Brown and Wouters, 1999).
Recently, macroautophagy (hereafter called autophagy; type II
programmed cell death), has also been reported to mediate cyto-
toxicity to these anti-cancer regimens (Zeng and Kinsella, 2007,
2010).
Autophagy is an evolutionarily conserved lysosomal pathway
for degrading cytoplasmic proteins and organelles in eukaryotic
cells (Dunn, 1990). The main physiologic function of autophagy
is to supervise and maintain cellular protein and organelle qual-
ity control, thereby preventing the accumulation of unfolded
and aggregated proteins so as to maintain intracellular meta-
bolic homeostasis (Dunn, 1990). Autophagy is involved in many
aspects of human health and disease, including cancer. Accumu-
lating evidence suggests that autophagy is a double-edged sword
in tumorigenesis, functioning as both a tumor suppressor and a
protector of cancer cell survival (Shintani and Klionsky, 2004).
A better understanding of autophagy regulation and its impact
on treatment outcomes will potentially allow the identiﬁcation
of novel therapeutic targets in cancer. In this review, we summa-
rize the current knowledge about autophagy machinery, crosstalk
between apoptosis and autophagy, and the impact of autophagy
on the anti-cancer treatment efﬁcacy of ionizing radiation and
chemotherapy in human cancers.
AUTOPHAGY MACHINERY
Autophagy is a ubiquitous cellular pathway in eukaryotic cells
that entails the degradation of intracellular components through
the lysosomal machinery (Dunn, 1990; Shintani and Klionsky,
2004). This cellular self-consumption process is characterized by
sequestration of bulk cytoplasm, long-lived proteins, and cellu-
lar organelles in double-membrane vesicles, called autophago-
somes. Autophagosomes form from the elongation of small mem-
brane structures called isolation membranes. These membranes
can be derived from the endoplasmic reticulum, trans-golgi net-
work, mitochondrial outer membrane, or the plasma membrane.
Autophagosomes then fuse with lysosomes, forming autolyso-
somes where its contents are degraded by lysosomal enzymes
(Figure 1; Shintani and Klionsky, 2004).
Autophagy is a highly regulated process. The process starts with
the activation of a Unc-51-like kinase (ULK) complex composed
of ULK1/2, Atg13, FIP200, and Atg101 (He and Klionsky, 2009;
Yang and Klionsky, 2010). This complex is regulated by mTOR
which senses nutrient levels in the environment. Under high-
nutrient conditions, mTOR phosphorylates ULK1/2 and then
inhibits autophagy; whereas mTOR dissociates from the ULK
complex during periods of nutrient deprivation and activates
autophagy (Figure 2A). The activation and accumulation of the
ULK complex result in the development of the isolation mem-
branes (He and Klionsky, 2009; Yang and Klionsky, 2010). The
subsequent development of autophagosomes is dependent on
a class III phosphatidylinositol-3 kinase (PI3K), also known as
Vps34, complex. The complex containing Beclin1–UVRAG (UV
radiation resistance associated gene) and Beclin1–Ambra1 acti-
vates autophagy, while the Beclin1–Rubicon complex negatively
regulates class III PI3K activity and inhibits autophagy (Yang and
Klionsky, 2010). The class III PI3K complex localizes to the iso-
lation membranes and recruits further Atgs like Atg3, Atg5, Atg7,
and LC3 [microtubule-associated protein light chain 3], to allow
for elongation of the isolation membranes and completion of the
autophagosomes (Figure 2B). Mediated by the lysosomal mem-
brane protein LAMP-2 and the small GTPase Rab7, autophago-
somes fuse with lysosomes, leading to the breakdown of proteins
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and organelles by lysosomal enzymes (Yang and Klionsky, 2010;
Amaravadi et al., 2011).
CROSSTALK BETWEEN APOPTOSIS AND AUTOPHAGY
Apoptosis, a form of programmed cell death (type I), has beenwell
characterized. It involves the activation of catabolic enzymes –
in particular proteases – in signaling cascades, which leads to
FIGURE 1 | Diagram of autophagy components.The initial phase of
autophagy is involved in the formation of isolation membranes. After
engulﬁng part of the cytoplasmic components, such as long-lived proteins
and organelles, the isolation membrane elongates and closes to become
autophagosomes. Autophagosomes then fuse with lysosomes and mature
into autolysosomes, resulting in the degradation of its contents.
FIGURE 2 | Molecular pathway of activation of autophagy. (A) In
presence of nutrients, active mTOR inhibits ULK1/2 – Atg13-FIP200-Atg101
complex through phosphorylating ULK1/2 and Atg13. In response to
nutrient deprivation, mTOR dissociates from the ULK complex, resulting in
dephosphorylation of ULK1/2 and Atg13 and subsequent induction of
autophagy. (B)The class III PI3K complex contains Vps34, p150, Beclin1,
UVRAG, and Ambra1. Rubicon negatively regulates class III PI3K activity
and inhibits autophagy. The class III PI3K complex localizes to the isolation
membranes and produces phosphatidylinositol-3-phosphate (PI3P),
allowing for elongation of the isolation membranes and completion of the
autophagosomes.
characteristic changes such as altered nuclear morphology includ-
ing chromatin condensation and fragmentation, cell shrink-
age, plasma membrane blebbing, and apoptotic body formation
(Williams, 1991).Although autophagy and apoptosis aremarkedly
different processes, several signalingmediators, as discussed below,
regulate both autophagic and apoptotic machinery.
COMMON SIGNAL TRANSDUCTION MEDIATORS
Reactive oxygen species not only trigger apoptosis but also stim-
ulate the proteolytic activity of Atg4 and then activate autophagy
(Scherz-Shouval et al., 2007). Ceramide is a prominent inducer
of apoptosis and also triggers autophagic cell death in malig-
nant glioma cells via activation of BNIP3 (Lavieu et al., 2006).
An increase in the cytosolic free Ca2+ concentration activates
pro-apoptotic signals while it also potently induces autophagy
through activating calmodulin-dependent kinase (Rizzuto and
Pozzan, 2006; Hoyer-Hansen et al., 2007). The tumor suppres-
sor p53 is a classic mediator of apoptosis (Vousden and Lane,
2007). However, accumulating evidence indicates that p53 stim-
ulates autophagy through inhibition of mTOR or activation of
damage-regulated autophagy modulator (DRAM; Crighton et al.,
2006; Zeng et al., 2007; Zeng and Kinsella, 2008).
DUAL ROLE OF Atg5 IN AUTOPHAGY AND APOPTOSIS
Atg5 (autophagy-related-5) also represents a point of crosstalk
between autophagic and apoptotic pathways. Atg5 is required for
autophagy. It conjugates to Atg12 and associates with isolation
membranes to form autophagosomes (Mizushima et al., 1998).
Interestingly, Atg5 also plays in an important role in the apoptotic
process. The role ofAtg5 in apoptosis ismediatedby theproteolytic
cleavage of Atg5. Upon lethal stress, the 33-kDa full-length Atg5
protein is cleavedbyCalpains to remove theC terminus,generating
a 24-kDa fragment. This fragment loses its autophagy-inducing
activity but acquires a pro-apoptotic function. The truncatedAtg5
fragment undergoes translocation from the cytosol to the mito-
chondria, where it associates with the anti-apoptotic molecule
Bcl-xL and then triggers apoptosis (Youseﬁ et al., 2006).
AUTOPHAGY FUNCTIONS AS A PRO-CELL SURVIVAL
MECHANISM IN MEDIATING RADIOTHERAPY AND
CHEMOTHERAPY DAMAGE
Substantial studies have shown that inhibition of autophagy sen-
sitizes cancer cells to DNA damaging anti-cancer reagents. Inhi-
bition of autophagy by 3-methyladenine (3-MA) and Atg7 siRNA
enhances 5-FU induced cytotoxicity in human colorectal cancer
cells (Li et al., 2010). Autophagy suppression also enhances the
therapeutic efﬁcacy of cisplatin and 5-FU in esophageal and colon
cancer cells, respectively (Liu et al., 2009; Li et al., 2010). siRNA-
mediated silencing of autophagy-related genes such as Beclin 1,
Atg3, and Atg4b sensitizes resistant cancer cells to ionizing radia-
tion (Apel et al., 2008). These studies suggest that autophagy may
provide amechanism throughwhich cancer cells acquire resistance
to radiotherapy and chemotherapy.
Cancer stem cells, a sub-population of cells with abilities to give
rise to all cell types found in a particular cancer sample, have been
shown to be highly resistant to ionizing radiation and other anti-
cancer treatments (Pajonk et al., 2010). It has been proposed that
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such therapy resistance may be due to increased autophagy in the
“stemcell”sub-population. For example, inmalignant gliomas, the
cancer stem cells, identiﬁed by CD133 positivity, express higher
levels of autophagy-related proteins including LC3, Atg5, and
Atg12. Higher levels of autophagy are induced in CD133+ can-
cer stem cells than in CD133− cells following ionizing radiation
(Lomonaco et al., 2009). Furthermore, glioma cells treated with
autophagy inhibitors exhibit more extensive DNA double-strand
breaks than cells treated with radiation alone (Ito et al., 2005).
These data suggest that cancer stem cells with increased autophagy
activity may provide one of the mechanisms of the resistance to
chemotherapy and ionizing radiation.
To reverse the pro-cell survival mechanism exerted by
autophagy, hydroxychloroquine (HCQ) or chloroquine (CQ)
are being studied in clinical trials as autophagy inhibitors to
enhance tumor cell killing when combined with chemotherapy
and radiotherapy. HCQ and CQ are widely used as anti-malarial
and anti-rheumatic agents. They disrupt lysosome acidiﬁca-
tion, thereby blocking the maturation of autophagosomes (Bel-
lodi et al., 2009). For example, in patients with glioblastoma,
a phase III clinical trial combining radiation and carmustine
with either daily CQ or placebo demonstrated a median sur-
vival of 24months in the CQ arm compared with 11months
in the placebo arm (Sotelo et al., 2006). However, the results
of this study were not statistically signiﬁcant, probably due
to a small sample size, but it does provide evidence for the
safety of adding CQ to current anti-cancer regimens and sug-
gests that CQ has the potential to improve patient survival.
Besides CQ and HCQ, there are other drugs and compounds
being investigated in pre-clinical stages as autophagy inhibitors.
Verteporﬁn, a benzoporphyrin derivative, has been shown to
inhibit autophagosome formation (Donohue et al., 2011).Another
small molecule, lucanthone, currently used as an anti-schistosome
agent, inhibits autophagy by impairing autophagic degradation
(Carew et al., 2011). Thus, there appears to be several classes of
autophagy inhibitors with the potential to sensitize cancer cells
to certain conventional chemotherapeutic drugs and to ionizing
radiation.
AUTOPHAGY FUNCTIONS AS A PRO-CELL DEATH
MECHANISM IN RADIOTHERAPY AND CHEMOTHERAPY
In contrast to its pro-survival role as discussed above, autophagy
has also been shown to function in type II programmed cell
death in other cancer cell lines following similar treatments with
chemotherapy or ionizing radiation. Stimulation of autophagy by
RAD001, a mTOR inhibitor, was shown to produce a synergistic
killing effect on papillary thyroid cancer cells by doxorubicin (Fuji-
wara et al., 2007). Akt inhibition induces autophagy and enhances
cell death when combined with chemotherapy as well (Degtyarev
et al., 2008). Induction of autophagy in papillary thyroid cancer
through mTOR inhibition has also been shown to increase cyto-
toxicity to ionizing radiation (Lin et al., 2010). Furthermore, it has
been reported that vitamin D or a vitamin D analog (compound
EB 1089) sensitizes breast cancer cells to ionizing radiation by
promoting autophagic cell death (Gewirtz et al., 2009). These data
indicate that autophagy also functions as a mechanism of pro-cell
death, depending on the cellular context.
One of the explanations that certain types of cancer cells
undergo autophagic cell death is that the apoptosis pathway is
inactivated in these cells. Substantial evidence suggests that apop-
tosis is often disabled in cancer cells due to frequent mutations
in apoptosis-inducing genes such as p53 and bax (Mrozek et al.,
2003). Thus, it is not surprising that tumor cells under extreme
stress often die by other mechanisms such as type II autophagic
cell death. Therefore, induction of autophagic cell death may be
an ideal approach in those cancers that are intrinsically resistant
to apoptosis following anti-cancer therapies (e.g., chemotherapy,
radiation).
To utilize the role of autophagy as a pro-cell death mechanism,
multiple pharmacologic agents are nowavailable for pre-clinical or
clinical testing to enhance the treatment efﬁcacy of chemotherapy
or ionizing radiation. The most commonly used autophagy-
inducers are the mTOR inhibitors. As a currently approved drug
for the treatment of renal cell carcinoma, Everolimus, a mTOR
inhibitor, induces autophagy and enhances sensitivity to ioniz-
ing radiation in prostate cancer and non-small-cell lung cancer
(NSCLC) cell lines and xenografts (Cao et al., 2006; Kim et al.,
2008). Multiple clinical trials with mTOR inhibitors are under
way to investigate the role of induction of autophagy in anti-
tumor activity. It has also been shown that the poly(ADP-ribose)
polymerase-1 (PARP1) inhibitor ABT-888 induces autophagy and
sensitize H460 NSCLC cells to ionizing radiation (Albert et al.,
2007). Other small molecules such as bortezomib (a proteasome
inhibitors), imatinib (a tyrosine kinase inhibitor), and tamox-
ifen (an antiestrogen) have been reported to induce autophagy
in human cancer cells as well (Janku et al., 2011). These data sug-
gest that autophagy-inducers hold great potential for improving
the treatment of cancers following chemotherapy and ionizing
radiation in the near future.
FIGURE 3 | A model for the impact of autophagy on chemotherapy and
radiotherapy mediated tumor cytotoxicity. In a tumor with a high
percentage of cancer stem cells, chemotherapy, or ionizing radiation can
increase autophagy activity in the stem cells, leading to the resistance of
the tumor to the treatments. In contrast, in cancer cells with disabled
apoptosis, autophagy may be activated as a type II programmed cell death
in response to chemotherapy or ionizing radiation.
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CONCLUDING REMARKS
The study of autophagy is a very exciting and highly promising
area of cancer research. There has been much recent progress in
our understanding the pathways that control autophagy. Further
exploration of these pathways holds great potential for improving
the treatment efﬁcacy of chemotherapy and ionizing radiation.
However, despite this potential, one of the most difﬁcult questions
remains to be answered: whether autophagy should be inhib-
ited or stimulated to improve clinical outcomes? As illustrated
in Figure 3, the impact of autophagy on chemotherapy and radio-
therapy mediated tumor cytotoxicity (to live or not to live) seems
to depend on the cellular context. Thus, gene expression signatures
may be identiﬁed as biomarkers to helpmake such decisions in the
future.
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